A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

• Status: Terminated
• Trial end date: 2020-09-09
• Target enrollment: 0
• Participant gender: All

Summary

This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in participants with rheumatoid arthritis (RA) who completed Study M16-063 (NCT03682705).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie
• Treatments: Upadacitinib

Criteria

Inclusion Criteria:

• Participant has completed Study M16-063

• Participant has not developed any laboratory or clinical discontinuation criteria as defined in the Study M16-063 protocol

• Participant is willing and/or able to comply with procedures required in the current study protocol

Exclusion Criteria:

• Participant is currently enrolled or planning to enroll in another interventional clinical study while participating in this study (except the preceding study M16-063)

• Participant requires vaccination with any live vaccine during study participation, including at least 30 days after the last dose of study drug